Mavyret

FDA issues safety warning for newer hepatitis C drugs following patient deaths
FDA issues safety warning for newer hepatitis C drugs following patient deaths
Biopharma Dive
FDA
hepatitis C
FAERS
AbbVie
Mavyret
Merck
Zepatier
Gilead Sciences
Vosevi
Flag link:
AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries
AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries
Fierce Pharma
AbbVie
hepatitis C
Mavyret
Medicines Patent Pool
Flag link:
Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
Bloomberg
Express Scripts
PBMs
Gilead Sciences
HIV
Atripla
AbbVie
Mavyret
hepatitis C
Flag link:
AbbVie surprised investors with its hepatitis C success. Will it last?
AbbVie surprised investors with its hepatitis C success. Will it last?
Biopharma Dive
AbbVie
hepatitis C
Mavyret
Flag link:
2 Reasons the Market Frowned After AbbVie's Blowout Q2 -- and 1 Reason It Should Be Excited
2 Reasons the Market Frowned After AbbVie's Blowout Q2 -- and 1 Reason It Should Be Excited
Motley Fool
AbbVie
earnings
Humira
Mavyret
Flag link:
As Humira competition nears, AbbVie's Imbruvica and Mavyret pick up steam
As Humira competition nears, AbbVie's Imbruvica and Mavyret pick up steam
Fierce Pharma
AbbVie
Humira
Imbruvica
Mavyret
Flag link:
This Small Biotech Is Building on a Surprising Success
This Small Biotech Is Building on a Surprising Success
Motley Fool
AbbVie
Mavyret
Enanta Pharmaceuticals
glecaprevir
hepatitis C
Flag link:
5 Must-See Quotes From AbbVie's Management
5 Must-See Quotes From AbbVie's Management
Yahoo/Motley Fool
AbbVie
Humira
hepatitis C
Mavyret
Viekira
M&A
Flag link:
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short
Fierce Pharma
AbbVie
Mavyret
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link:
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
Motley Fool
Merck
Keytruda
AbbVie
Humira
Mavyret
Bristol-Myers Squibb
Eliquis
Pfizer
Ibrance
Flag link:
There's a Lot to Like in AbbVie's Q3 Update
There's a Lot to Like in AbbVie's Q3 Update
Motley Fool
AbbVie
earnings
Humira
Imbruvica
Mavyret
Flag link:
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
Marketwatch
AbbVie
hepatitis C
Mavyret
Gilead Sciences
Merck
Flag link:
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Motley Fool
AbbVie
Gilead Sciences
hepatitis C
Mavyret
Flag link:
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
Fierce Pharma
AbbVie
hepatitis C
Mavyret
drug pricing
Flag link: